![una acalendar una acalendar](https://thumbs.dreamstime.com/z/calendario-del-planeamiento-de-la-semana-en-los-colores-del-d%C3%ADa-57970760.jpg)
Una acalendar series#
HIV infection with CD4 percentages ≥15% and CD4 count ≥200 cells/mm3 for at least 6 months and no evidence of immunity to measles, mumps, or rubella: 2-dose series at least 4 weeks apart MMR contraindicated for HIV infection with CD4 percentage Nonpregnant women of childbearing age with no evidence of immunity to rubella: 1 dose.Pregnancy with no evidence of immunity to rubella: MMR contraindicated during pregnancy after pregnancy (before discharge from health care facility), 1 dose.* Note: Anyone age 60 years or older who does not meet risk-based recommendations may still receive Hepatitis B vaccination. Travel in countries with high or intermediate endemic hepatitis B.Percutaneous or mucosal risk for exposure to blood (e.g., household contacts of HBsAg-positive persons residents and staff of facilities for developmentally disabled persons health care and public safety personnel with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids hemodialysis, peritoneal dialysis, home dialysis, and predialysis patients patients with diabetes).
![una acalendar una acalendar](https://labsfabs.com/imgs001/img_3756.jpg)
Sexual exposure risk (e.g., sex partners of hepatitis B surface antigen -positive persons sexually active persons not in mutually monogamous relationships persons seeking evaluation or treatment for a sexually transmitted infection men who have sex with men).Chronic liver disease (e.g., persons with hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase or aspartate aminotransferase level greater than twice upper limit of normal).Age 60 years or older* and at risk for hepatitis B virus infection: 2-dose (Heplisav-B) or 3-dose (Engerix-B, Recombivax HB) series or 3-dose series HepA-HepB (Twinrix) as above.Settings for exposure, including health care settings targeting services to injection or noninjection drug users or group homes and nonresidential day care facilities for developmentally disabled persons (individual risk factor screening not required).Pregnancy if at risk for infection or severe outcome from infection during pregnancy.Close, personal contact with international adoptee (e.g., household or regular babysitting) in first 60 days after arrival from country with high or intermediate endemic hepatitis A (administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee’s arrival).Travel in countries with high or intermediate endemic hepatitis A (HepA-HepB may be administered on an accelerated schedule of 3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).Work with hepatitis A virus in research laboratory or with nonhuman primates with hepatitis A virus infection.Chronic liver disease (e.g., persons with hepatitis B, hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase or aspartate aminotransferase level greater than twice the upper limit of normal).At risk for hepatitis A virus infection: 2-dose series HepA or 3-dose series HepA-HepB as above.1 dose Tdap each pregnancy 1 dose Td/Tdap for wound management ( see notes)ġ dose Tdap, then Td or Tdap booster every 10 yearsĢ doses for immunocompromising conditions ( see notes)Ģ or 3 doses depending on age at initial vaccination or conditionĢ, 3, or 4 doses depending on vaccine or conditionġ or 2 doses depending on indication, see notes for booster recommendationsĢ or 3 doses depending on vaccine and indication, see notes for booster recommendations